In vivo assessments confirmed the two HSPC phenotype and perform (reconstitution likely) have been not impaired by systemic anti-Dll4 therapy, and in vitro differentiation of HSPCs gathered from the BM of anti-Dll4 dealt with mice was also not impaired, which means HSPCs are unaffected by in vivo anti-Dll4 therapy (Figure 3B, 4B and S6)
The world wide BM vessel identification is thus altered upon anti-Dll4 therapy. Apparently, CD31...